Sprouty is a cytoplasmic target of adenoviral E1A oncoproteins to regulate the receptor tyrosine kinase signalling pathway by Zaremba, Angelika et al.
RESEARCH Open Access
Sprouty is a cytoplasmic target of adenoviral E1A
oncoproteins to regulate the receptor tyrosine
kinase signalling pathway
Angelika Zaremba
1*, Ursula Schmuecker
2 and Helmut Esche
2
Abstract
Background: Oncoproteins encoded by the early region of adenoviruses have been shown to be powerful tools
to study gene regulatory mechanisms, which affect major cellular events such as proliferation, differentiation,
apoptosis and oncogenic transformation. They are possesing a key role to favor viral replication via their interaction
with multiple cellular proteins. In a yeast two-hybrid screen we have identified Sprouty1 (Spry1) as a target of
adenoviral E1A Oncoproteins. Spry proteins are central and complex regulators of the receptor tyrosine kinase (RTK)
signalling pathway. The deregulation of Spry family members is often associated with alterations of the RTK
signalling and its downstream effectors, leading to the ERK pathway.
Results: Here, we confirm our yeast two-hybrid data, showing the interaction between Spry1 and E1A in GST pull-
down and immunoprecipitation assays. We also demonstrated the interaction of E1A with two further Spry
isoforms. Using deletion mutants we identified the N-terminus and the CR conserved region (CR) 3 of E1A- and the
C-terminal half of Spry1, which contains the highly conserved Spry domain, as the essential sites for direct
interaction between Spry and E1A. Immunofluorescent microscopy data revealed a co-localization of E1A13S with
Spry1 in the cytoplasm. SRE and TRE reporter assays demonstrated that co-expression of Spry1 with E1A13S
abolishes the inhibitory function of Spry1 in RTK signalling, which is consequently accompanied with a decrease of
E1A13S-induced gene expression.
Conclusions: These results establish Spry1 as a cytoplasmic localized cellular target for E1A oncoproteins to
regulate the RTK signalling pathway, and consequently cellular events downstream of RTK that are essential for
viral replication and transformation.
Background
Proteins encoded by the early transcription unit 1A
(E1A) of Adenovirus (Ad) are essential for the viral life
cycle because of their necessity in regulating the expres-
sion of all other viral genes [1]. In addition these proteins
modulate the expression of specific cellular genes in
infected cells to facilitate viral reproduction [2,3]. E1A
oncoproteins cooperate with Ad early region 1B (E1B)
oncogene products to transform rodent cells in culture
and, depending on the serotype, to induce tumors in
immunocompetent animals (e.g. Ad12) [4-6]. Ad12 E1A
gives rise to five proteins of which the 266R protein
(translated from a 13S mRNA; henceforth referred to as
E1A13S) and the 235R protein (translated from a 12S
mRNA; henceforth referred to E1A12S)a r et h ep r e d o m i -
nant isoforms [2,7]. Both proteins are translated in the
same reading frame but differ in a short stretch of 31 aa,
c a l l e dC R 3 ,t h a ti sa b s e n ti nE 1 A 12S. CR3 is one of four
E1A regions (CR1, CR2, CR3 and CR4) that are highly
conserved among all Adenovirus serotypes [2]. The N
terminus and the CRs of E1A mediate most of the gene
regulatory functions necessary for viral reproduction and
transformation [8]. Due to the lack of a sequence-specific
DNA binding activity, E1A proteins, mainly known as
transcription factors, fulfill their gene regulatory func-
tions by interaction with cellular transcription factors
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cellular co-factors like p300 and CBP [9-12].
The idea that E1A is also capable of exerting its regula-
tory functions by directly affecting cytoplasmic processes
was supported by the discovery that a certain amount of
E1A proteins is acetylated at Lys
239, which determines
the cytoplasmic localization of E1A proteins by interfer-
ing with the nuclear transport [13]. Until now, a few
cytoplasmic localized interaction partners of E1A have
been identified including the regulatory subunit II of pro-
tein kinase A (PKA-RIIa) [14], the receptor for activated
C-kinase l (Rackl) [15,16], and the cytoplasmic protea-
some 26S [17].
Sprouty (Spry) proteins have been identified as regula-
tory proteins of the receptor tyrosine kinase (RTK) sig-
nalling pathway [18-21]. They appear to play an
inhibitory role in many cellular events due to their effect
on RTK, especially in FGF-dependent developmental
processes [22-25]. First identified in Drosophila [19],
Sprouty homologues have been discovered in human and
mouse. A high degree of conservation of key functional
amino acids has been shown for Spry proteins among dif-
ferent species [20,22,26,27].
A unique and highly conserved C-terminal cysteine-rich
Spry domain has been identified for all 4 mammalian Spry
isoforms. The Spry domain is responsible for palmitoyla-
tion at the plasma membrane. Mutations in this region
disrupt membrane localization and abrogate Spry func-
tions [22,28,29]. A conserved short N-terminal tyrosine-
containing motif of Spry was discovered to be critical for
physiological functions to inhibit FGF signalling and sus-
tain EGF signalling [30,31]. Different interacting partners
have been identified, which upon binding with Spry conse-
quently influence RTK signalling pathway, including Rafl,
Grb2, c-Cbl and Shp2 [28,31-33]. The deregulation of
Sprouty was described in a number of cancers [34-38].
In a search to identify potential cytoplasmic binding part-
ners of Adenovirus E1A oncoproteins we detected Spry1 as
a putative binding partner of E1A. We were able to con-
firm this interaction in GST pull-down and immunopreci-
pitation assays. We also demonstrated an interaction of
two further Spry isoforms with E1A and characterized the
protein domains that are responsible for binding. Using
confocal immunofluorescence microscopy, we detected a
co-localization of Spry1 and E1A13S exclusively in the cyto-
plasm. Co-expression of E1A13S with Spry1 indicated a
functional role for this interaction to modulate RTK signal-
ling pathway and thereby to regulate cellular processes.
Results
Sprouty proteins interact with E1A isoforms
In a previous search for cellular targets of adenoviral pro-
teins using a mouse embryo cDNA-expression library
(Chevrayx and Nathans, Howard Huges Medical
Institute, Baltimore) and a SOS-yeast two hybrid system
we detected mouse Spry1 as a cytoplasmic interaction
partner of Ad12 E1A proteins (data not shown). In order
to confirm this observation, we first examined the bind-
ing of Spry1 and further Spry proteins with Ad12 E1A
isoforms by GST pull-down assays. Mouse Spry1, Spry2
and Spry4 were exogenously expressed in HeLa cells and
incubated with E1A13S,-, E1Al2S- and E1A9,5S-GST-fusion
proteins (Figure 1A). Spry1 and Spry4 interact with all
three Ad12 E1A isoforms (Figure 1B). For Spry2 we were
not able to detect an interaction with E1A12S and E1A9.5S
showed only weak binding. The mutant ΔNE1A12S,a n
isoform where we deleted the first 29 amino acids of the
N terminus, showed no interaction with Spry1 and Spry2
(Figure 1B). However, for Spry4 we were able to detect
an interaction with ΔNE1A12S, indicating an essential
function of the Ad12 E1A N-terminal domain for effi-
cient interaction with Spry1 and Spry2. Although weak,
we surprisingly detected an interaction between Spry1
and the analog aminoterminal deletion mutant of the
E1A13S isoform, indicating that the conserved region 3
( C R 3 )i sa l s oi n v o l v e di nb i n d i n gw i t hS p r y 1 .H o w e v e r
the domain of E1A that is responsible for the interaction
with Spry4 remains to be elucidated. To further define
the region of Spry1 that is necessary for binding with
E1A we constructed two deletion mutants in which we
truncated either the N-terminal (ΔNSpry1) or the C-
terminal half of Spry1 (ΔCSpry1) (Figure 1A). Our data
showed that the C-terminal half of Spry1, bearing the
highly conserved Spry domain, is necessary for the inter-
action with E1A, whereas the tyrosine-containing
sequence of the N-terminal part is not essential for inter-
action (Figure 1C). Since the Spred family of proteins are
likewise Sprouty-domain-containing proteins that show
regulatory functions in RTK signalling pathway [39,40],
we studied the interaction of E1A proteins with mouse
Spred1 and Spred2 by GST pull-down assays. In our
experiments, we were not able to detect any interactions
between Spred proteins and E1A isoforms (data not
shown). It’s possible that conformational changes due to
additional binding domains [such Ena/Vasp homolog
(EVH)1 and c-Kit binding (KBD)-domain] in Spred pro-
teins prevent E1A from binding with this protein family
[20].
To confirm whether the interaction of E1A with Spry
occurs in cells we co-expressed Spry1 and Myc-tagged
E1A12S proteins in HeLa cells. Cell lysates were subjected
to immunoprecipitation with anti-Spry1 antibody, and
the immunoprecipitates were then analyzed for the pre-
sence of Myc-tagged E1A12S. Results from these experi-
ments have confirmed that E1A12S binds Spry1 in
mammalian cells (Figure 1D).
To verify if the interaction with Spry proteins is
restricted to E1A proteins of the highly ongogenic
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Figure 1 Sprouty proteins interact with E1A isoforms. (A) Schematic representation of the E1A wild type isoforms E1A13S, E1A12S, E1A9.5S, the
deletion mutants ΔNE1A13S and ΔNE1A12S (with a deletion of the first 29 N-terminal amino acids) and Spry isoforms and deletion mutants
(ΔNSpry1 with a deletion of amino acids 1-173; ΔCSpry1 with a deletion of amino acids 174-313). Red boxes in E1A proteins represent the
conserved regions 1 to 4; the brown box in Spry represents the Spry domain and the blue box the conserved tyrosine phosphorylation site. (B,
C) For GST pull-down assays HeLa cell extract, containing the isoform Spry1, Spry2 or Spry4 (B) or the Spry-mutants ΔNSpry1 or ΔCSpry1 (C) were
incubated with the protein leader sequence GST- or GST-E1A-fusion proteins as indicated. 0.5 mg of cellular lysate and 40 μg of GST-E1A or GST
were incubated at 4°C for 1 h. Proteins bound were subjected to SDS-PAGE, and immunoblot analysis was performed with antibodies directed
against the Myc-epitope of Spry-fusion proteins. * The higher molecular weight band may represent post-translational modification of Spry1
(palmitoylation and phosphorylation) as reported before [22]. (D) For immunoprecipitation HeLa cells were transiently co-transfected with Spry1
and Myc-tagged E1A12S expression vectors as indicated. Cell extracts were prepared 48 h post transfection and incubated with anti-Spry1
antibodies. Interacting proteins were precipitated and analyzed on SDS-PAGE by Western blotting using anti-Spry1 and anti-Myc antibodies.
Transient expression was examined in the total lysate (Δ co-eluted antibody heavy chains).
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Page 3 of 12adenovirus serotype 12 (Ad12), we examined the inter-
action of the non-oncogenic adenovirus serotype 2
(Ad2) E1A13S protein with Spry1 and were able to detect
an interaction (Figure 2A).
Spry1 interacts with the Human papillomavirus type 16
(HPV16) E7 protein
The E7 oncoprotein of the Human Papillomavirus type
16 (HPV16-E7) displays partial amino acid sequence
homology, comparable function, and similar interaction
partners with adenoviral E1A oncoproteins [41,42].
Therefore, we examined and confirmed the interaction
of Spry1 with the HPV16-E7 protein by GST pull-down
a s s a y( F i g u r e2 B ) .A sap o s i t i v ec o n t r o lw eu s e dG S T -
E1A13S and as a negative control we used GST in the
pull down assay. Our results establish Spry proteins as
potential targets of presumably various DNA tumor
virus oncoproteins.
Spry1 co-localizes with E1A13S in the cytoplasm
To determine the subcellular localization of Spry1 in the
presence of E1A proteins, we performed confocal immu-
nofluorescence microscopy using antibodies that specifi-
cally recognize Spry1 and Myc-tagged E1A13S.H e L a
cells were serum-deprived overnight and treated with
bFGF for 2 h. Whereas Spry1 was distributed within the
whole cytoplasm, E1A13S was predominantly found in
the nucleus (Figure 3) with a lesser amount of E1A13S
detectable in the cytoplasm. This cytoplasmic pool of
E1A13S strongly co-localized with Spry1, predominantly
in vesicular structures within the cytoplasm (Figure 3C).
In addition, the subcellular localization of Spry1 is not
affected by the presence of E1A proteins.
Co-expression of Spry1 decreases E1A13S-induced gene
transactivation of TRE and SRE
In transient expression assays we examined the effect of
Spry1 and E1A13S interaction on gene expression activity.
First, we analyzed this effect on the TPA-responsive ele-
ment (TRE) in HeLa cells, which is transactivated by E1A
and c-Jun [43,44]. Our results showed that the expression
of the collagenase (Col)-TREd r i v e nr e p o r t e rg e n ei s
down-regulated after Spry1 expression and up-regulated
due to the ectopic expression of E1A13S, whereas it is
highly up-regulated when E1A13S and c-Jun are co-
expressed. The E1A13S-induced gene transactivation was
again repressed by co-expression with Spry1 (Figure 4).
These data indicate that Spry1 decreases E1A13S-induced
gene expression. Because Spry1 is known to act as a
repressing factor in RTK signalling pathways, it is concei-
vable that co-expression of Spry1 represses E1A-induced
gene expression by inhibiting the activity of specific
kinases involved in transcriptional activation. To gain
further insight into how the direct interaction of E1A13S
with Spry1 functionally influences gene transactivation
we decided to choose another reporter construct. The
serum response element (SRE) is known to be downregu-
lated by Spry proteins in response to bFGF treatment
[23,45]. In our experiments cells were serum deprived for
24 h prior to stimulation with 10% FCS or 20 ng/ml
bFGF for 1, 5, 7 and 9 hours. In HeLa cells, we detected a
2 to 3 fold increase in reporter gene activation in
response to E1A13S expression after 5 - 9 h incubation
with FCS, whereas in C33A and NIH-3T3 cell lines an
upregulation of promoter activity by E1A13S was already
detectable after 1 h of FCS stimulation (Figure 5). Similar
results were obtained using bFGF instead of FCS for
induction of the RTK signalling pathway after serum
deprivation (Figure 6A). In cells that express both pro-
teins, E1A13S abolishes the repression function of Spry1,
whereby the E1A13S-induced gene expression activity
consequently decreases by up to more than 50%. Concen-
tration-dependent reporter assays showed a decrease of
E1A13S promoter activation in response to an increase of
Spry1 co-expression. Whereas the ability of Spry1 to
reduce gene expression activity is abolished in response
to an increase of E1A13S co-expression (Figure 7).
In co-expression experiments in which we expressed
E1A12S instead of E1A13S however, we could not detect
an increase in SRE-promoter activity and therefore no
significant change after co-expression of Spry1 as well
(data not shown).
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Figure 2 Spry1 interacts with E1A13S of the non-oncogenic
Adenovirus type 2 (Ad2) and with the Human papillomavirus
type 16 (HPV16) E7 protein. Lysates from cell extracts expressing
Spry1 were incubated with (A) GST-Ad2-E1A13S and (B) GST-HPV16-
E7-fusion proteins or for control reactions with the leader sequence
GST or GST-Ad12-E1A13S as indicated. The assays were performed
with 0.5 mg of cellular lysate and 40 μg of GST-fusion proteins at 4°
C for 1 h. The bound proteins were subjected to SDS-PAGE and
analyzed by immunoblotting. Spry1 was detected by an antibody
directed against the Myc-epitope of the Spry-fusion protein.
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Page 4 of 12Using the E1A13S N-terminal deletion mutant
(ΔNE1A13S) in such transient expression assays, we were
unable to detect a decrease of ΔNE1A13S induced gene
expression in response to Spry1 compared with studies
using wild type E1A13S (Figure 6). Also, the co-expres-
sion of ΔNE1A13S with Spry1 after 7 h and 9 h of stimu-
lation showed a slightly higher SRE-dependent gene
expression compared with cells expressing ΔNE1A13S
exclusively. Our GST pull-down data showed that Spry1
interacts only weakly with ΔNE1A13, suggesting that the
stronger interaction with Spry1 mediated by the N-ter-
minus of E1A might be necessary for the inhibitory
effect of Spry1 to repress E1A13S activity. Moreover it is
worthwhile to note that these data also show that SRE
can be activated by E1A13S independent of its N-term-
inal amino acids.
Co-expression of Spry1 and E1A13S specifically impairs
phosphorylation of ERK1/2 MAP kinase
It is reported that Spry1 inhibits the Ras/Raf/MAP
kinase pathway [23]. To examine if the SRE-dependent
reporter gene expression is affected by the ERK1/2 MAP
kinase pathway, we analyzed the phosphorylation of
ERK1/2 in HeLa cells after expression of Spry1 and
E1A13S or ΔNE1A13S. A decrease in phosphorylation of
ERK1/2 was detected in cells expressing Spry1, as com-
pared with cells that were transfected with an empty
expression plasmid, when visualized by phospho-specific
antibodies. Expression of E1A13S in these cells led to an
increased phosphorylation of ERK1/2 after 1 h of bFGF
treatment, whereas the addition of Spry1 inhibited
ERK1/2 phosphorylation (Figure 6C). For comparison
we assayed the influence of ΔNE1A13S on ERK1/2 phos-
phorylation in the presence of Spry1. As expected, we
were not able to detect an inhibition of the ERK1/2
phosphorylation/activation after co-expression of Spry1
and ΔNE1A13S (Figure 6C). Confirming the SRE repor-
ter assays, a slight increase in phosphorylation was
detectable in cells expressing Spry1 and ΔNE1A13S com-
pared to cells only expressing ΔNE1A13S. To summerize,
these results support our hypothesis of a functional
interaction between E1A oncoproteins and Spry1 in the
cytoplasm to modulate the Ras/Raf/MAP kinase
pathway.
Discussion
E1A oncoproteins have a key role in adenoviral replica-
tion. Their specific interaction with cellular proteins
induces viral and cellular gene expression which initiates
the host cell to enter S-Phase and therefore enables the
virus life cycle to continue [46]. E1A binding partners
are therefore specific targets that enable the virus to
modulate the cell cycle. In this study, we identified Spry
proteins as cytoplasmic interacting partners of adeno-
viral E1A proteins. Since Spry proteins are known as the
“regulator” of RTK signalling pathway we studied and
demonstrated the ability of E1A to modulate RTK sig-
nalling pathway through specific interaction with Spry1.
The mammalian Spry family consists of four Spry pro-
teins. In our GST pull-down assays we showed differ-
ences in binding affinity of E1A isoforms with specific
Spry family members (Spry1, Spry2, Spry4) which might
reflect various interaction mechanisms and potential dif-
ferences in functions of Spry isoforms. Here we
observed a strong binding of Ad12 E1A proteins with
Spry1 and Spry2, mediated via the aminoterminal E1A-
sequence and furthermore the responsibility of CR3 for
a less strong interaction with Spry1. Interestingly, the
Spry1 E1A13S Merged
A B C A B C
Figure 3 Spry1 co-localizes with E1A13s in the cytoplasm. The subcellular localization of Spry1 and E1A13s was determined in HeLa cells by
confocal immunofluorescence microscopy using antibodies that specifically recognize Spry1 (green) and the Myc-tagged E1A13s (red) protein
constructs. (A) Spry1 and (B) E1A13s transfected cells were left serum starved overnight and stimulated with 20 ng/ml bFGF for 2 h. (C) Images
were overlaid for comparison of staining, yellow indicates co-localization of the two proteins. Scale bar, 10 μm.
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proteins is responsible for the interaction with two
further cytoplasmic proteins, the 26S proteasom and the
PKA-RIIa [14,17]. However, the amino acids involved in
the interaction of these proteins are still unknown.
Moreover we discovered the C-terminal half of Spry1,
including the Spry domain, as the responsible region for
E1A interaction. However, the Spry-domain-containing
Spred proteins showed no interaction with E1A. It has
yet to be clarified whether Spry-domain-neighbouring
amino acids or variable amino acids within the con-
served Spry domain mediate the interaction with E1A.
Conformational changes between Spry and Spred pro-
teins due to their Ena/Vasp homolog (EVH)1 and c-Kit
binding (KBD)-domain, which is missing in Spry, may
prevent E1A from binding [20].
We detected Spry1 accumulated and associated with
E1A13S in vesicular structures within the whole cyto-
plasm. A localization of Spry proteins in vesicular struc-
tures has been reported before [22,47]. Palmitoylation
targets Spry to the plasma membrane, which has been
shown to be a necessary step for the inhibitory function
of Spry in RTK signalling pathway [22,29].
Using TRE or SRE luciferase reporter assays we analyzed
the functional consequences on gene expression activity by
E1A13S and Spry1. The decrease of reporter gene expres-
sion by Spry1 was abolished when co-expressed with
E1A13S. Expression of constant amounts of Spry1 and
increasing amounts of E1A13S proteins showed that Spry1
proteins are functionally inactivated by E1A13S and vice
versa. A functional repression of Spry1 would lead to an
increasing activity of the RTK signalling pathway and to an
increasing amount of phosphorylated transcription factors
which could therefore enhance E1A-induced gene expres-
sion. This observation was supported by our experiments
analyzing the phosphorylation of ERK. Overexpression of
Spry1 decreased E1A13S-induced ERK-phosphorylation in
comparison to the expression of E1A alone.
The up- or down-regulation of Spry has been described
in different cancers [48], indicating the necessity of a
balanced function of Spry proteins. Our data indicate that
Spry1 is an important target of E1A proteins in the cyto-
plasm to modulate the RTK signalling pathway to influ-
ence cellular processes for optimizing viral replication.
Using the aminoterminal deletion mutant of E1A13S
we obtained unexpected data. ΔNE1A13S displays only a
weak binding with Spry1 via the CR3 in GST pull-down
assays (Figure 1B) and can still increase reporter gene
expression, whereas in co-expression with Spry1 no sig-
nificant repression was detectable (Figure 6B). Possibly,
the interaction via the CR3 has different effects on
Figure 4 E1A13 inhibits Spry1 down-regulation of the Col-TRE
driven reporter gene. (A) Schematic representation of the reporter
construct 3xcolTRE-tk-Luc; the Luciferase expression is driven by the
thymidine kinase promoter of the herpes simplex virus (tk, nt -105
to +51) and three copies of the TRE sequence of the human
collagenase gene (colTRE, nt -73 to -65). (B, C) HeLa cells were co-
transfected with the colTRE-Luc reporter construct (0.5 μg),
expression vectors (0.5 μg) coding for E1A13S and/or Spry1 and c-
Jun as indicated. Empty expression vectors were added to keep the
amount of transfected DNA constant. 63 h after transfection cells
were lysed and Luciferase activity was determined. Total lysates
were immunoblotted to monitor the presence of expressed proteins
with respective antibodies against E1A13S, Spry1 and c-Jun. Results
are mean ± S.E.M. between duplicates.
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Page 6 of 12Figure 5 Spry1 decreases E1A13s induced SRE transactivation in different cell lines. (A) HeLa cells, (B) C33A cells and (C) NIH-3T3 cells were
co-transfected with the SRE-Luc reporter construct (1 μg) and with plasmids (0.5 μg) expressing E1A13S and/or Spry1 as indicated. Empty
expression vectors were added to keep the amount of transfected DNA constant. After transfection cells were left serum-deprived for 24 h and
then incubated with 10% FCS in DMEM. Serum stimulation was performed for the indicated times (white, 1 h; cross line, 5 h; horizontal line, 7 h;
dots, 9 h). The promotor activity of the reporter gene in the presence of empty vectors was set as 1. (D) Expression of Spry1 and E1A13S in the
lysates was confirmed in Western blot assays. Results are mean ± S.E.M. between duplicates and representative for 3 individual experiments.
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Page 7 of 12Figure 6 Spry1 decreases wild type E1A13S induced gene expression but not ΔNE1A13S transactivation through ERK1/2 kinase
phosphorylation. (A) HeLa cells were co-transfected with the reporter construct SRE-Luc (1 μg) and plasmids (0.5 μg) expressing Spry1 and/or
E1A13S or ΔNE1A13S as indicated. Empty expression vectors were added to keep the amount of the transfected DNA constant. After transfection
cells were left serum-deprived for 24 h and then incubated with 20 ng/ml bFGF in DMEM. Serum stimulation was performed for the indicated
times (white, 1 h; cross line, 5 h; horizontal line, 7 h; dots, 9 h). The promotor activity of the reporter gene in the presence of empty vectors was
set as 1. Data represents mean ± S.E.M. of n ≥ 4. * p < 0.05 (B) Expression of Spry1 and E1A13S in the lysates was confirmed in Western blot
assays. (C) HeLa cells expressing Spry1 and/or E1A13S or ΔNE1A13S were serum starved overnight, followed by incubation for 1 h with 20 ng/ml
bFGF in DMEM. Cells were lysed and lysates were subjected to SDS-PAGE and analyzed by immunoblotting. The membranes were incubated
with antibodies directed against phosphorylated ERK1/2 (phospho-ERK1/2), unphosphorylated ERK1/2 (ERK1/2) and antibodies directed against
Spry1 and E1A13S.
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Page 8 of 12Spry1 function compared to the combined interaction
via the N-terminus and the CR3 domain of E1A13S.
These results were also supported by our phosphoryla-
tion studies of ERK, indicating an important N-term-
inal-dependent function of Ad12 E1A proteins for the
interaction with Spry1. It is conceivable that the interac-
tion mediated exclusively via the CR3 has a different
effect on Spry1 function than the interaction mediated
via the N-terminus and the CR3 domain of E1A13S.
Instead of acting exclusively as inhibitors in signal trans-
duction Spry proteins can be also involved in sustaining
signal activity. This function dependents on the activity
of binding partners such as c-Cbl [31,49,50]. The
transcriptional gene expression activity of ΔNE1A13S
and the interaction of Spry1 exclusively with the CR3 of
E1A13S might cause a different influence on Spry1 func-
tion and would therefore explain our results using the
E1A deletion mutant. Further studies are necessary to
understand the mechanism of interaction between E1A
and Sprouty proteins in detail.
Conclusion
In conclusion, our results show for the first time that
Spry proteins are targets of adenoviral E1A oncopro-
teins, which enables the virus to modulate the RTK sig-
nalling, leading to the ERK pathway, and to control, in
Figure 7 Concentration-dependent suppression of Spry1 function by E1A13S. HeLa cells were co-transfected with the SRE-Luciferase
reporter construct and different concentrations of expression plasmids coding for Spry1 and/or E1A13S. We used either constant amounts of
Spry1- (A) or E1A13S-expression vectors (B) in our experiments as indicated. Empty expression vectors were added to keep the amount of
transfected DNA constant. After transfection cells were left serum-deprived for 24 h and followed by incubation with 20 ng/ml bFGF in DMEM.
The promotor activity of the reporter gene in the presence of empty vectors was set as 1.
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Page 9 of 12addition to its transcriptional functions, cellular pro-
cesses like proliferation, differentiation and apoptosis.
The fact that Spry1 interacts with E7 of HPV 16 leads
to the speculation that this might be a more general
way of DNA viruses to modulate RTK signalling path-
ways. Over the past few years increasing evidence is
implicating Spry in tumorgenesis and cancer [34,35,38].
Our identification and analysis of the functional interac-
tion between the viral oncoprotein E1A and Spry sup-
port the idea of Spry being an important factor in
tumorgenesis.
Methods
Cells, Growth Factors, Transfection Methods
HeLa, C33A and NIH-3T3 cells were cultured in Dulbec-
co’s modified Eagle’s medium with 10% fetal calf serum
(FCS). For GST pull-down assay mouse Spry1, Spry2 and
Spry4 were transfected by electroporation with the
ECM830 electroporator. Cells were transfected by Trans-
Fectin Lipid reagent (Biorad) for co-immunoprecipitation
and luciferase assays. For growth factor stimulation, cells
were washed and maintained in serum-reduced medium
(Dulbecco’s modified Eagle’s medium with 0.5% newborn
calf serum) for 24 h prior to fetal calf serum/ bFGF (Invi-
trogen) treatment. Cells were harvested after several
hours as indicated.
DNA Constructs
T h en u c l e o t i d es e q u e n c eo fm u r i n eS p r y 1 ,S p r y 2a n dS p r y 4
are listed under AF176903, AF176905 and AF176906,
respectively. Myc-tagged mouse Spry1 and Spry2 cDNAs
cloned in plasmid pSG9M were a gift of Prof. G. Christo-
fori (Basel, Swizerland) and the Myc-tagged mouse Spry4
cDNA cloned in plasmid pcDNA3 was a gift of Prof. A.
Yoshimura (Fukuoka, Japan). Nucleotide sequences of
GST-E1A-fusion proteins were cloned into the vector
pGEX-2t (Pharmacia Biotech). Vector GST-E7pGEX-2t
expressing the E7 protein of HPV16 was a gift of Prof. D.J.
McCance (Rochester, New York). The N-terminal (residues
1-173) and C-terminal (residues 173-313) DNA fragments
of mouse Spry1 and the Adenovirus E1A deletion mutants
ΔNE1A13S, (residues 30-266) and ΔNE1A12S,( r e s i d u e s3 0 -
235) were generated using standard polymerase chain reac-
tion and molecular cloning methods. For co-immunopreci-
pitation, Spry1 was cloned via BamHI-XhoI sequences into
the vector pcR3.1 (Invitrogen). E1A13S and E1A12S were
cloned via BamHI sites into the vector pcDNA3.1/myc-His
(-)B (Invitrogen). Mouse c-Jun was purchased from rzpd
(clone ID: IRAVp968D0544D) and was cloned into the
vector pcR3.1 (Invitrogen). The pGL3/Col-TRE reporter
construct contains three colTRE-elements followed by the
tk promoter of the herpes simplex virus, and the pGL3/
SRE-Luc reporter construct contains five serum response
elements (Stratagene). All constructs were sequenced.
Immunoblot Analysis
Cells were lysed (10 mM Tris, pH 7.4, 5 mM MgCl2,1 5 0
mM NaCl, 0.5% NP40, 1 mM 4-(2-Aminoethy1)-Benzene-
SulfonylfluorideCl (Pefabloc SC) (Biomol)), proteins were
separated by SDS-PAGE and transferred to Hybond-C
Extra nitrocellulose membrane (Amersham Bioscience).
T h ef o l l o w i n gp r i m a r ya n t ibodies were used: mouse
monoclonal anti-Myc (Invitrogen); rabbit polyclonal anti-
Sprouty1 (H120; Santa Cruz); rabbit polyclonal anti-c-JUN
(H-79; Santa Cruz); rabbit anti-Ad12E1A antiserum (Gen-
ovac); rabbit polyclonal anti-phospho-p44/42 MAP kinase
(#9101; NEB); rabbit polyclonal anti-p44/42 MAP kinase
(#9102; NEB). For detection, one of the following second
antisera were used: peroxidase goat anti-mouse IgG (H+L)
(Pierce) at 1/50000; peroxidase goat anti-rabbit IgG (H+L)
(Pierce) at 1/50000. Membranes were developed using
ECL (Pierce; Amersham Pharmacia Biotech).
GST pull-down assay
Glutathione Sepharose 4B was purchased from Amersham
Bioscience. For preclearing, 0.5 mg of cellular lysate were
incubated with 50 μl of Glutathion Sepharose (50%) for 1
h at 4°C. Subsequently, after washing by centrifugation at
500 × g for 5 min, supernatants were incubated with 40 μg
of GST-fusion protein for 1 h at 4°C. The proteins bound
were subjected to SDS-PAGE and immunoblot analysis
was performed as described above.
Co-Immunoprecipitation
Cells were lysed with RIPA buffer (Santa Cruz) and pre-
cleared with control IgG (Santa Cruz) and 20 μl of Protein
A/G Plus-agarose (Santa Cruz). 0.5 mg of the cell lysates
were incubated with 1.6 μg of the precipitating antibody for
1.5 h at 4°C while gentle rocking. 20 μlo fP r o t e i nA / G
Plus-agarose were added for overnight incubation. The
beads were collected by centrifugation, washed 3 times with
1 ml of lysis buffer, and boiled in 40 μl 2 × SDS sample buf-
fer. The immunoprecipitates were fractioned by SDS-PAGE
and analyzed by immunobloting as described above.
Immunofluorescence
HeLa cells (0.25 × 10
5) were seeded onto sterilized glass
coverslips contained in 24-well plates. After transfection,
cells were maintained in serum-reduced medium over-
night and stimulated with 20 ng/ml bFGF for various
times. The cells were rinsed with PBS, fixed with 3% paraf-
ormaldehyde in PBS for 15 min at room temperature, per-
meabilized with 0.1% Triton X-100 for 4 min at room
temperature, and washed with PBS. After blocking with
1% BSA/PBS for 30 min, cells were incubated with the pri-
mary antibody (mouse monoclonal anti-Myc (Invitrogen);
rabbit polyclonal anti-Sprouty 1 (H120) (Santa Cruz)) for
1 h at room temperature. After washing with PBS, cells
were incubated with the secondary antibody (Alexa Fluor
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Page 10 of 12488 goat anti-rabbit IgG (Invitrogen); Cy3-conjugated goat
anti-mouse IgG (dianova)) for l h at room temperature.
After the final wash each coverslip was prepared for
microscopic examination by applying mounting medium
(Mowiol, Hoechst AG).
Luciferase Assay
Cells were transfected by TransFectin Lipid reagent
(Biorad) and Luciferase activity in cell lysates was measured
by using the Promega-Luciferase assay system in a Berthold
Lumat LB 9501 luminometer. In all reporter assays, 2.5 ×
10
5 HeLa or C33A cells or 1.8 × 10
5 NIH-3T3 cells were
plated on 6-well dishes.
Statistics
All measured values are expressed as the mean ± S.E.M.
The significance of the results was analyzed using
Student’st - t e s t .
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